Surrozen is a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues and organs damaged by serious disease. Surrozen is designing tissue-specific antibodies that engage the body’s own biological repair mechanisms resulting in a broad pipeline of disease-specific therapies to help patients across multiple disease areas, including severe liver diseases, inflammatory bowel disease, retinopathies, hearing loss, lung and airway diseases, and certain neurological disorders. Surrozen is focused on engaging the body’s own biological repair mechanisms through tissue-specific modulation of the Wnt pathway to discover and develop a broad pipeline of first-in-class, targeted regenerative antibodies. In June 2020, it raised $50 million in Series C financing. Investors from the Series B financing participated in the Series C round, including The Column Group, Hartford Healthcare Trust, and Horizons Ventures. Four new investors also participated in this recent financing round, including Euclidian Capital.
